DDInter632 DDInter122
Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D. Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces ﬂuid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale.
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Eluxadoline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Probenecid
Eluxadoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Eluxadoline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxilaprevir
Eluxadoline {u} may lead to a major life threatening interaction when taken with {v} Darolutamide
Eluxadoline {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Eluxadoline may cause a minor interaction that can limit clinical effects when taken with Probenecid
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Voxilaprevir
Eluxadoline may lead to a major life threatening interaction when taken with Darolutamide
Eluxadoline may lead to a major life threatening interaction when taken with Saquinavir